The shareholders of Eckert & Ziegler AG will resolve on the measure at the upcoming Annual General Meeting, which is expected to take place on 7 June 2023 in Berlin. The effectiveness of the conversion into the legal form of an SE also requires that the procedure for the agreement on the involvement of employees in the future Eckert & Ziegler SE is completed or terminated before registration.
"With the change of legal form, we want to underline Eckert & Ziegler’s positioning as a future-oriented international healthcare company," explains Dr Harald Hasselmann, member of the Executive Board of Eckert & Ziegler AG.
The SE conversion will fundamentally not affect the legal position of the shareholders of Eckert & Ziegler AG. Shareholders will hold the same number of no-par-value shares in Eckert & Ziegler SE. The listing of EZAG shares in the Prime Standard of the Frankfurt Stock Exchange will also remain unaffected by the change of legal form, so that the shares of the future Eckert & Ziegler SE will continue to have the previous ISIN DE0005659700 and WKN 565970.
Eckert & Ziegler Strahlen- und Medizintechnik AG with nearly 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
http://www.ezag.de
Öffentlichkeitsarbeit
Telefon: +49 (30) 941084-138
Fax: +49 (30) 941084-112
E-Mail: karolin.riehle@ezag.de
